New cocktail therapy targets tough pancreatic cancer
NCT ID NCT05481476
First seen Oct 31, 2025 · Last updated May 22, 2026 · Updated 32 times
Summary
This study tests a combination of three drugs (surufatinib, sintilimab, and AG) as the first treatment for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this mix can shrink tumors and delay cancer growth. The trial involves 32 participants and is currently active but not recruiting new patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cancer center of SunYat-sen University
Guangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.